Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib in ED-SCLC
NCT02735980Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of prexasertib in small cell lung cancer (SCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate at 10 months. Started May 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02735980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735980.